Effect of Sacubitril/Valsartan on Echocardiographic Parameters in HFrEF Patients
1Mahnoor Laghari, 2Fazeela Rizwan, 3Dr Shoaib Sarwar Hashmi, 4Muzna Hameed Dar, 5Munira Khursheed, 6Mashkoor Ansari
Submission: 15 February 2026 | Acceptance: 10 March 2026 | Publication: 03 April 2026
1Lecturer in department of pharmacology Bilawal medical college Jamshoro
2Lecturer in department of pharmacology Bilawal medical college Jamshoro
3SR Cardiology CPEIC Wazirabad
4Assistant professor in department of pharmacology Bilawal medical college Jamshoro
5Mphil trainee in department of pharmacology Liaquat university of medical health sciences Jamshoro
6Associate Professor in department of pharmacology Liaquat university of medical health sciences Jamshoro
ABSTRACT:
BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) continues to be one of the leading causes of cardiovascular illness and death. An angiotensin receptor neprilysin inhibitor, Sacubitril/Valsartan, seems to enhance cardiac function via reverse remodeling. This study seeks to evaluate the change in echocardiographic parameters after administering the drug for three months.
METHODS: This study was a prospective observational study conducted with a sample of 76 patients diagnosed with HFrEF (LVEF < 40%). Along with Echocardiographic measures, a patient’s age and gender, associated illnesses, socioeconomic status, and in some cases lab results were registered. During the study, LVEF, LVEDd, and SWT were measured three months’ post therapy to evaluate the impact of Sacubitril/Valsartan. Results were analyzed using paired t-test.
RESULTS: Between baseline and three months, there was a marked LVEF improvement from 31.5% ± 3.3 to 46.3% ± 4.2 (p < 0.001). Also, LVEDd was noted to decrease to 51.3 ± 4.3 mm from 57.8 ± 4.3 mm (p < 0.001) and SWT was noted to reduce from 10.1 ± 0.8 mm to 8.7 ± 0.6 mm (p < 0.001). All patients exhibited these changes.
CONCLUSION: There is a significant improvement of echocardiographic parameters in HFrEF patients after taking Sacubitril/Valsartan, demonstrating its efficacy.